Cytotheryx vs Regeneron

Side-by-side comparison of AI visibility scores, market position, and capabilities

Regeneron leads in AI visibility (75 vs 23)
Cytotheryx logo

Cytotheryx

EmergingBioTech

Cell Therapy / Liver Disease

Raised $60M Series A (Jan 2026) led by Ouroboros Capital. Mayo Clinic spinout. Engineered pigs as bio-incubators for human hepatocyte production at scale.

AI VisibilityBeta
Overall Score
D23
Category Rank
#1 of 1
AI Consensus
71%
Trend
up
Per Platform
ChatGPT
26
Perplexity
15
Gemini
21

About

Cytotheryx is a Mayo Clinic spinout developing human hepatocytes (liver cells) produced at scale using genetically engineered pigs as bio-incubators. The company raised $60 million in Series A financing in January 2026 led by Ouroboros Capital, with GMP (Good Manufacturing Practice) manufacturing expansion underway to support both its acute liver failure support program and transplant-grade cell therapy pipeline.

Full profile
Regeneron logo

Regeneron

LeaderLife Sciences & BioTech

Biopharmaceuticals

Tarrytown NY biopharma giant; creator of Dupixent (>$14B revenue), Eylea, and Kevzara. Velocity Genome platform drives fast antibody and bispecific drug discovery.

AI VisibilityBeta
Overall Score
B75
Category Rank
#2 of 2
AI Consensus
73%
Trend
up
Per Platform
ChatGPT
72
Perplexity
76
Gemini
84

About

Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized mouse technology that dramatically accelerates the discovery of human antibodies—and has used it to produce multiple best-in-class biologics across inflammatory, oncologic, and eye diseases.\n\nRegeneron's commercial portfolio is anchored by Dupixent (dupilumab), developed with Sanofi, which has become one of the best-selling drugs globally with over $14 billion in 2024 revenues, treating atopic dermatitis, asthma, COPD, and other type-2 inflammatory conditions. Additional key products include Eylea (aflibercept) for macular degeneration and PRALUENT for cardiovascular cholesterol lowering. The company's bispecific antibody pipeline, cancer vaccines in collaboration with BioNTech, and gene therapy programs represent its next growth wave.\n\nRegeneron reported over $14 billion in annual revenue in 2024 and maintains a world-class science culture, consistently ranking among the top companies for R&D productivity and employee satisfaction. Its Tarrytown campus houses more than 10,000 employees and remains a leading independent US biopharmaceutical innovator.

Full profile

AI Visibility Head-to-Head

23
Overall Score
75
#1
Category Rank
#2
71
AI Consensus
73
up
Trend
up
26
ChatGPT
72
15
Perplexity
76
21
Gemini
84
21
Claude
77
27
Grok
79

Key Details

Category
Cell Therapy / Liver Disease
Biopharmaceuticals
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Cytotheryx
Cell Therapy / Liver Disease
Only Regeneron
Biopharmaceuticals

Integrations

Only Regeneron

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.